Neuraxis posts preliminary Q1 2026 results

Neuraxis, Inc. released preliminary, unaudited figures for the quarter ended March 31, 2026.

Rhea-AI Filing Summary

Neuraxis, Inc. released preliminary, unaudited figures for the quarter ended March 31, 2026. The Company expects cash and cash equivalents of about $7.1 million as of that date, providing a snapshot of its available liquidity.

For the same three-month period, Neuraxis anticipates net sales of approximately $1.6 million, up from about $0.9 million a year earlier, showing strong year-over-year revenue growth. On a preliminary basis, it expects gross profit of about $1.4 million and an operating loss of about $1.7 million, indicating the business is still not profitable.

The Company emphasizes these numbers are preliminary and unaudited and may change as the quarter-end close is completed and the independent registered public accounting firm reviews the full financial statements.

Insights

Equity research analyst

Neuraxis shows strong Q1 revenue growth but remains loss-making.

Neuraxis expects net sales of about $1.6 million for the quarter ended March 31, 2026, up from roughly $0.9 million a year earlier. This implies rapid top-line growth while generating a preliminary gross profit of about $1.4 million.

Despite this progress, the Company still projects an operating loss of approximately $1.7 million for the quarter, so profitability remains a challenge. Liquidity appears supported by expected cash and cash equivalents of about $7.1 million as of March 31, 2026.

All figures are preliminary and unaudited, and management notes that final results could change as the financial close and external review proceed. Subsequent quarterly filings will show whether revenue growth continues and operating losses narrow.

8-K Event Classification

Item 2.02 — Results of Operations and Financial Condition

1 item

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Key Figures

Cash and cash equivalents: $7.1 million Net sales Q1 2026: $1.6 million Net sales Q1 2025: $0.9 million +2 more

5 metrics

Cash and cash equivalents $7.1 million As of March 31, 2026 (preliminary)

Net sales Q1 2026 $1.6 million Three months ended March 31, 2026 (preliminary)

Net sales Q1 2025 $0.9 million Three months ended March 31, 2025 (prior-year comparison)

Gross profit Q1 2026 $1.4 million Three months ended March 31, 2026 (preliminary)

Operating loss Q1 2026 $1.7 million Three months ended March 31, 2026 (preliminary)

Key Terms

operating loss, gross profit, preliminary unaudited, independent registered public accounting firm, +1 more

5 terms

operating loss financial

"expects its gross profit to be approximately $1.4 million, and its operating loss to be approximately $1.7 million"

Operating loss occurs when a company’s regular business activities—sales of goods or services—bring in less money than it costs to run the business, like a shop whose daily sales don’t cover rent and wages. For investors, it signals that the core business isn’t currently profitable, which can increase cash burn, affect future dividends or financing needs, and change how the company’s value and risk are judged.

gross profit financial

"the Company expects its gross profit to be approximately $1.4 million"

Gross profit is the amount a business keeps from sales after subtracting the direct costs to make or buy the products or services sold — like the money left from a lemonade stand after paying for lemons, sugar and cups. Investors watch gross profit to judge how well a company’s core operations and pricing cover those direct costs, revealing its basic profitability and whether margins are improving or shrinking over time.

preliminary unaudited financial

"on a preliminary unaudited basis, the Company expects its cash and cash equivalents"

Preliminary unaudited means reported financial figures are an early, draft version that have not yet been checked and signed off by an independent auditor. Think of it like a first draft of a school report: it gives a useful snapshot of performance but may contain errors or adjustments before it becomes final. Investors care because numbers can change after review, so preliminary unaudited results carry more uncertainty when valuing a company or making trading decisions.

independent registered public accounting firm regulatory

"The Company’s independent registered public accounting firm has not audited, reviewed or performed any procedures"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

Section 18 of the Securities Exchange Act of 1934 regulatory

"shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934"

Earnings Snapshot

Net sales: $1.6 million

Q1 2026

Net sales $1.6 million from approximately $0.9 million for the three months ended March 31, 2025

Gross profit $1.4 million

Operating loss $1.7 million

Cash and cash equivalents $7.1 million

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What preliminary Q1 2026 revenue did Neuraxis (NRXS) report?

Neuraxis expects net sales of approximately $1.6 million for the three months ended March 31, 2026. This compares to about $0.9 million in the same period of 2025, indicating strong year-over-year revenue growth based on management’s preliminary, unaudited estimates.

What is Neuraxis’ expected operating loss for Q1 2026?

Neuraxis anticipates an operating loss of approximately $1.7 million for the quarter ended March 31, 2026. This reflects that, despite revenue growth and a projected gross profit of about $1.4 million, the Company has not yet reached overall profitability this quarter.

How much cash does Neuraxis (NRXS) expect to have as of March 31, 2026?

Neuraxis expects to report cash and cash equivalents of about $7.1 million as of March 31, 2026. This preliminary figure offers insight into the Company’s liquidity position before final first-quarter financial statements are completed and reviewed by its independent registered public accounting firm.

Are Neuraxis’ Q1 2026 figures audited or final?

The Q1 2026 figures are preliminary and unaudited. Management states these estimates may change as the quarter-end close process finishes and the independent registered public accounting firm performs its work, so investors are cautioned against placing undue reliance on the initial numbers.

How did Neuraxis’ Q1 2026 gross profit compare to revenue?

Neuraxis projects gross profit of about $1.4 million on net sales of roughly $1.6 million for Q1 2026. This suggests a high gross margin on a preliminary basis, though the Company still expects an operating loss of approximately $1.7 million for the quarter.

What period do Neuraxis’ preliminary results in this 8-K cover?

The preliminary results cover the three months ended March 31, 2026. Neuraxis provides early estimates for net sales, gross profit, operating loss, and cash as of March 31, 2026, and plans to finalize its full financial statements for this period after this disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/21/2026 - 05:28 PM Learn about SEC filing dates

false 0001933567 0001933567 2026-04-21 2026-04-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 21, 2026

Neuraxis, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41775		45-5079684
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

11611 N. Meridian St, Suite 330 Carmel, IN 46032

(Address of principal executive offices)

Registrant’s telephone number, including area code: (812) 689-0791

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		NRXS		NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition

On April 21, 2026, Neuraxis, Inc. (the “Company”), issued disclosure that, on a preliminary unaudited basis, the Company expects its cash and cash equivalents to be approximately $7.1 million as of March 31, 2026. The Company expects its net sales to be approximately $1.6 million for the three months ended March 31, 2026, as compared to approximately $0.9 million for the three months ended March 31, 2025. On a preliminary unaudited basis, the Company expects its gross profit to be approximately $1.4 million, and its operating loss to be approximately $1.7 million, for the three months ended March 31, 2026. As we complete our quarter-end financial statement close process and finalize our financial statements and accompanying notes for the three months ended March 31, 2026, the Company will be required to make significant judgments in a number of areas that may result in the estimates provided herein being different than the final reported amounts.

These preliminary estimates have been prepared by and are the responsibility of the Company’s management. The Company’s independent registered public accounting firm has not audited, reviewed or performed any procedures with respect to these preliminary estimates or the accounting treatment thereof and does not express an opinion or any other form of assurance with respect thereto. The Company expects to complete its financial statements for the three months ended March 31, 2026 subsequent to the filing of this Item 2.02 8-K. It is possible that the Company or its independent registered public accounting firm may identify items that require the Company to make adjustments to these preliminary estimates and those changes could be material. Accordingly, undue reliance should not be placed on these preliminary estimates.

The information contained in Item 2.02 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and such information is not incorporated by reference into any registration statements or other document filed under the Securities Act of 1933, as amended or the Exchange Act, regardless of the general incorporation language contained in such filing, except as shall be expressly set forth by specific reference to this filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:	April 21, 2026	NEURAXIS, INC.
		By:	/s/ Brian Carrico
		Name:	Brian Carrico
		Title:	President and Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB